Format

Send to

Choose Destination
Amyloid. 2001 Jul;8 Suppl 1:28-35.

Glycosaminoglycan mimetics: a therapeutic approach to cerebral amyloid angiopathy.

Author information

1
Neurochem Inc, St-Laurent, Quebec, Canada. fgervais@neurochem.com

Abstract

Amyloid deposits characteristic of cerebral amyloid angiopathy lead to vessel rupture and intracerebral hemorrhage. Proteoglycans associate with the amyloid fibril deposits and are thought to play a role in the polymerization of amyloid proteins and the propagation of the deposition process. A series of low molecular weight anionic compounds was developed to mimic the glycosaminoglycan moieties of these proteoglycans. These compounds were tested in different in vitro systems to determine their anti-Abeta amyloid activity. Specific compounds were identified as being anti-fibrillogenic and protective against Abeta-induced cvtotoxicity. Such compounds also did not show intrinsic cellular toxicity could cross the blood-brain barrier (BBB) in vivo, and showed a good safety profile following chronic' exposure. Molecules showing an anti-amyloid profile combined with the ability to cross the BBB represent promising therapeutics for CAA.

PMID:
11676287
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center